Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
Seres Therapeutics, Inc. ( MCRB ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Carlo Tanzi Marella Thorell - Co-CEO, Co-President & CFO Matthew Henn - Executive VP & Chief Scientific Officer Dennis M. Walling - Senior VP of Clinical Development & Head of Clinical Research Teresa Young - Executive VP and Chief Commercial & Strategy Officer Conference Call Participants John Newman - Canaccord Genuity Corp., Research Division Joseph Thome - TD Cowen, Research Division Presentation Operator Good day, everyone, and thank you for standing by.
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Carlo Tanzi - Corporate Participant Investor Relations - Corporate Participant Dennis M. Walling - Senior VP of Clinical Development & Head of Clinical Research Marella Thorell - Co-CEO, Co-President & CFO Matthew R.
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Thorell - Chief Financial Officer Matthew Henn - Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer Dennis Walling - Senior Vice President, Clinical Development Conference Call Participants Caroline Pötsch-Hennig - JPMorgan Joseph Thome - TD Cowen John Newman - Canaccord Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Executive Vice President and Chief Medical Officer Matthew Henn - Executive Vice President and Chief Scientific Officer Terri Young - Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell - Executive Vice President and Chief Financial Officer Chris McChalicher - Senior Vice President, Manufacturing, Quality and Process Development Conference Call Participants Joseph Thome - TD Cowen Caroline Pocher - JPMorgan Edward Tenthoff - Piper Sandler John Newman - Canaccord Genuity Operator Thank you for standing by. My name is Kate, and I will be your conference operator today.
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - Chief Executive Officer Lisa von Moltke - Chief Medical Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Marella Thorell - Chief Financial Officer Matthew Henn - EVP, Chief Scientific Officer Conference Call Participants Joseph Thome - TD Cowen Caroline Pocher - JPMorgan Edward Tenthoff - Piper Sandler Operator Thank you for standing by. My name is Bella, and I will be your conference operator today.
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also gets potential future milestone payments of up to $275 million. Promising Phase 1b data for SER-155 shows potential in preventing bacterial infections in immunocompromised patients, positioning it as a new value driver.
